The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

The Shuman Law Firm Investigates ViroPharma, Inc.

Wednesday, August 22, 2012

The Shuman Law Firm Investigates ViroPharma, Inc.15:16 EDT Wednesday, August 22, 2012 BOULDER, Colo. (Business Wire) -- The Shuman Law Firm today announced that it is investigating potential claims against certain officers and directors of ViroPharma Incorporated ("ViroPharma" or the "Company") (Nasdaq: VPHM). The firm's investigation concerns the Company's supplemental new drug application ("sNDA") approval for the drug Vancocin and December 14, 2011 statements that Vancocin would qualify for three additional years of exclusivity against generic competition. On April 10, 2012, the Company disclosed that not only did the Food and Drug Administration (“FDA”) advise the Company that the sNDA approval would not qualify for exclusivity, but, the FDA concurrently announced the approval of three applications for generic capsules. These events have led to the filing of numerous lawsuits against the Company. If you currently own ViroPharma common stock and are interested in discussing your rights as a shareholder, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at (866) 974-8626 or email Mr. Shuman at or email Mr. Glenn at The Shuman Law Firm represents investors throughout the nation, concentrating its practice in securities class actions and shareholder derivative actions. The Shuman Law FirmKip B. Shuman, Esq., 866-974-8626kip@shumanlawfirm.comorRusty E. Glenn, Esq., 866-974-8626rusty@shumanlawfirm.comFax: